Journal article icon

Journal article

Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.

Abstract:
Thirty-eight of 295 subjects participating in a randomized, double-blind, placebo-controlled trial of the efficacy of daily administration of atovaquone/proguanil for malaria prevention developed malaria at some time during the 20-week prophylaxis period. These subjects (3 atovaquone/proguanil recipients and 35 placebo recipients) were treated with 4 tablets of atovaquone/proguanil per day for 3 days. Atovaquone/proguanil provided safe, well-tolerated, and effective therapy for uncomplicated malaria in nonimmune Indonesians.
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1086/343750

Authors


Maguire, JD More by this author
Barcus, MJ More by this author
Expand authors...
Journal:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume:
35
Issue:
9
Pages:
e92-e95
Publication date:
2002-11-05
DOI:
EISSN:
1537-6591
ISSN:
1058-4838
URN:
uuid:ee6be04d-e4eb-42a0-8cdd-30e95099a32a
Source identifiers:
81574
Local pid:
pubs:81574

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP